- Home
- AIM vs CLDI Comparison
AIM vs CLDI Comparison
Compare AIM & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- CLDI
- Stock Information
- Founded
- AIM 1966
- CLDI 2014
- Country
- AIM United States
- CLDI United States
- Employees
- AIM N/A
- CLDI N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIM Health Care
- CLDI Health Care
- Exchange
- AIM Nasdaq
- CLDI Nasdaq
- Market Cap
- AIM 15.9M
- CLDI 18.1M
- IPO Year
- AIM N/A
- CLDI N/A
- Fundamental
- Price
- AIM $0.20
- CLDI $1.47
- Analyst Decision
- AIM Strong Buy
- CLDI Strong Buy
- Analyst Count
- AIM 2
- CLDI 3
- Target Price
- AIM $2.75
- CLDI $16.67
- AVG Volume (30 Days)
- AIM 403.8K
- CLDI 1.2M
- Earning Date
- AIM 11-15-2024
- CLDI 11-12-2024
- Dividend Yield
- AIM N/A
- CLDI N/A
- EPS Growth
- AIM N/A
- CLDI N/A
- EPS
- AIM N/A
- CLDI N/A
- Revenue
- AIM $190,000.00
- CLDI N/A
- Revenue This Year
- AIM N/A
- CLDI N/A
- Revenue Next Year
- AIM $1,086.80
- CLDI N/A
- P/E Ratio
- AIM N/A
- CLDI N/A
- Revenue Growth
- AIM N/A
- CLDI N/A
- 52 Week Low
- AIM $0.16
- CLDI $0.73
- 52 Week High
- AIM $0.62
- CLDI $18.50
- Technical
- Relative Strength Index (RSI)
- AIM 40.44
- CLDI 37.87
- Support Level
- AIM $0.20
- CLDI $1.60
- Resistance Level
- AIM $0.23
- CLDI $2.17
- Average True Range (ATR)
- AIM 0.02
- CLDI 0.20
- MACD
- AIM 0.00
- CLDI -0.08
- Stochastic Oscillator
- AIM 10.75
- CLDI 5.37
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.